Posttransplant diabetes mellitus in kidney transplant recipients receiving calcineurin or mTOR inhibitor drugs

Motoo Araki, Stuart M. Flechner, Hazem R. Ismail, Lawrence M. Flechner, Lingmei Zhou, Ithaar H. Derweesh, David Goldfarb, Charles Modlin, Andrew C. Novick, Charles Faiman

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

Background. The aim of this study was to evaluate the incidence and risk factors for posttransplant diabetes mellitus (PTDM; defined as new insulin use and/or new hyperglycemia) in 528 kidney recipients using different immunosuppressive agents. Methods. Maintenance therapy included mycophenolate mofetil or azathioprine plus glucocorticoids in combination with Group I cyclosporine (263); Group II tacrolimus (60); or Group III sirolimus (205). Results. The mean follow-up was 39.2 (range 9.0-103.8) months. Overall, the number of patients needing insulin was 7.4% (39/528). The incidences for Groups I, II, and III of 7.6%, 11.7%, and 5.9%, respectively, were not statistically different. Characteristics of patients with PTDM included older age (P=0.007); greater body weight (kg) at transplant, 6 months, and 12 months, respectively (P2) at transplant, 6 months, and 12 months, respectively (P

Original languageEnglish
Pages (from-to)335-341
Number of pages7
JournalTransplantation
Volume81
Issue number3
DOIs
Publication statusPublished - Feb 2006
Externally publishedYes

Fingerprint

Calcineurin
Diabetes Mellitus
Insulin
Mycophenolic Acid
Transplants
Kidney
Incidence
Azathioprine
Tacrolimus
Sirolimus
Immunosuppressive Agents
Hyperglycemia
Pharmaceutical Preparations
Cyclosporine
Glucocorticoids
Body Weight
Transplant Recipients
Therapeutics

Keywords

  • Cyclosporine
  • Diabetes
  • Glucocorticoids
  • Immunosuppression
  • Kidney transplantation
  • Mycophenolate mofetil
  • Sirolimus
  • Tacrolimus

ASJC Scopus subject areas

  • Transplantation
  • Immunology

Cite this

Posttransplant diabetes mellitus in kidney transplant recipients receiving calcineurin or mTOR inhibitor drugs. / Araki, Motoo; Flechner, Stuart M.; Ismail, Hazem R.; Flechner, Lawrence M.; Zhou, Lingmei; Derweesh, Ithaar H.; Goldfarb, David; Modlin, Charles; Novick, Andrew C.; Faiman, Charles.

In: Transplantation, Vol. 81, No. 3, 02.2006, p. 335-341.

Research output: Contribution to journalArticle

Araki, M, Flechner, SM, Ismail, HR, Flechner, LM, Zhou, L, Derweesh, IH, Goldfarb, D, Modlin, C, Novick, AC & Faiman, C 2006, 'Posttransplant diabetes mellitus in kidney transplant recipients receiving calcineurin or mTOR inhibitor drugs', Transplantation, vol. 81, no. 3, pp. 335-341. https://doi.org/10.1097/01.tp.0000195770.31960.18
Araki, Motoo ; Flechner, Stuart M. ; Ismail, Hazem R. ; Flechner, Lawrence M. ; Zhou, Lingmei ; Derweesh, Ithaar H. ; Goldfarb, David ; Modlin, Charles ; Novick, Andrew C. ; Faiman, Charles. / Posttransplant diabetes mellitus in kidney transplant recipients receiving calcineurin or mTOR inhibitor drugs. In: Transplantation. 2006 ; Vol. 81, No. 3. pp. 335-341.
@article{353513eac2954bb0b4703766c178c70b,
title = "Posttransplant diabetes mellitus in kidney transplant recipients receiving calcineurin or mTOR inhibitor drugs",
abstract = "Background. The aim of this study was to evaluate the incidence and risk factors for posttransplant diabetes mellitus (PTDM; defined as new insulin use and/or new hyperglycemia) in 528 kidney recipients using different immunosuppressive agents. Methods. Maintenance therapy included mycophenolate mofetil or azathioprine plus glucocorticoids in combination with Group I cyclosporine (263); Group II tacrolimus (60); or Group III sirolimus (205). Results. The mean follow-up was 39.2 (range 9.0-103.8) months. Overall, the number of patients needing insulin was 7.4{\%} (39/528). The incidences for Groups I, II, and III of 7.6{\%}, 11.7{\%}, and 5.9{\%}, respectively, were not statistically different. Characteristics of patients with PTDM included older age (P=0.007); greater body weight (kg) at transplant, 6 months, and 12 months, respectively (P2) at transplant, 6 months, and 12 months, respectively (P",
keywords = "Cyclosporine, Diabetes, Glucocorticoids, Immunosuppression, Kidney transplantation, Mycophenolate mofetil, Sirolimus, Tacrolimus",
author = "Motoo Araki and Flechner, {Stuart M.} and Ismail, {Hazem R.} and Flechner, {Lawrence M.} and Lingmei Zhou and Derweesh, {Ithaar H.} and David Goldfarb and Charles Modlin and Novick, {Andrew C.} and Charles Faiman",
year = "2006",
month = "2",
doi = "10.1097/01.tp.0000195770.31960.18",
language = "English",
volume = "81",
pages = "335--341",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Posttransplant diabetes mellitus in kidney transplant recipients receiving calcineurin or mTOR inhibitor drugs

AU - Araki, Motoo

AU - Flechner, Stuart M.

AU - Ismail, Hazem R.

AU - Flechner, Lawrence M.

AU - Zhou, Lingmei

AU - Derweesh, Ithaar H.

AU - Goldfarb, David

AU - Modlin, Charles

AU - Novick, Andrew C.

AU - Faiman, Charles

PY - 2006/2

Y1 - 2006/2

N2 - Background. The aim of this study was to evaluate the incidence and risk factors for posttransplant diabetes mellitus (PTDM; defined as new insulin use and/or new hyperglycemia) in 528 kidney recipients using different immunosuppressive agents. Methods. Maintenance therapy included mycophenolate mofetil or azathioprine plus glucocorticoids in combination with Group I cyclosporine (263); Group II tacrolimus (60); or Group III sirolimus (205). Results. The mean follow-up was 39.2 (range 9.0-103.8) months. Overall, the number of patients needing insulin was 7.4% (39/528). The incidences for Groups I, II, and III of 7.6%, 11.7%, and 5.9%, respectively, were not statistically different. Characteristics of patients with PTDM included older age (P=0.007); greater body weight (kg) at transplant, 6 months, and 12 months, respectively (P2) at transplant, 6 months, and 12 months, respectively (P

AB - Background. The aim of this study was to evaluate the incidence and risk factors for posttransplant diabetes mellitus (PTDM; defined as new insulin use and/or new hyperglycemia) in 528 kidney recipients using different immunosuppressive agents. Methods. Maintenance therapy included mycophenolate mofetil or azathioprine plus glucocorticoids in combination with Group I cyclosporine (263); Group II tacrolimus (60); or Group III sirolimus (205). Results. The mean follow-up was 39.2 (range 9.0-103.8) months. Overall, the number of patients needing insulin was 7.4% (39/528). The incidences for Groups I, II, and III of 7.6%, 11.7%, and 5.9%, respectively, were not statistically different. Characteristics of patients with PTDM included older age (P=0.007); greater body weight (kg) at transplant, 6 months, and 12 months, respectively (P2) at transplant, 6 months, and 12 months, respectively (P

KW - Cyclosporine

KW - Diabetes

KW - Glucocorticoids

KW - Immunosuppression

KW - Kidney transplantation

KW - Mycophenolate mofetil

KW - Sirolimus

KW - Tacrolimus

UR - http://www.scopus.com/inward/record.url?scp=32844474104&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=32844474104&partnerID=8YFLogxK

U2 - 10.1097/01.tp.0000195770.31960.18

DO - 10.1097/01.tp.0000195770.31960.18

M3 - Article

C2 - 16477217

AN - SCOPUS:32844474104

VL - 81

SP - 335

EP - 341

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 3

ER -